This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
Hepatitis C’s genotype 3 can be hard to cure, but researchers presenting a study at the Liver Meeting (AASLD) in San Francisco, CA, said they have found a regimen that works.
Vincent LeRoy, MD, of the Centre Hospitalier Universitaire de Grenoble, La Tronche France, and colleagues at other institutions reported on a trial known as ALLY-3+.
Fifty patients with HCV-GT-3 were treated and most had already had other treatments. The patients got daclatasvir (Daklinza/Bristol-Myers-Squibb) sofosbuvir (Sovaldi/Gilead) and ribavirin (Rebetol/Merck). One arm of the group got the combo for 12 weeks and showed SVR4 rate of 88%. A second group took the drugs for 16 weeks and their SVR4 rate was 96%.
There were no virologic breakthroughs.
In an abstract presented at the meeting, the team concluded that the combination therapy “Achieved high SVR4 rates” in patients with HCV GT3 with compensated advanced fibrosis or cirrhosis “and was generally safe and well tolerated.”